Kerri Fitzgerald

DocwireNews

The U.S. Food and Drug Administration (FDA) warned that some heartburn drugs, including Zantac&reg; (ranitidine), contain low levels of N-nitrosodimethylamine (NDMA), a nitrosamine impurity&nbsp;that is classified as a probable human carcinogen that could cause cancer.NDMA is a known environmental contaminant that is found in water and foods, including meats, dairy products, and vegetables. <a href="https://www.docwirenews.com/docwire-pick/fda-recalls-medications-containing-valsartan-cancer-risk/">The FDA has been investigating NDMA</a> and other nitrosamine impurities in blood pressure and heart failure drugs since last year, for which the FDA has recommended numerous recalls for medications with unacceptable levels of nitrosamines.<h2>No recalls yet&mdash;more research needed</h2>The FDA is still evaluating whether the low levels of NDMA found in ranitidine pose a risk to patients.&nbsp;So far, the agency said that the level of NDMA in these products is very low, and at this time, there have been no recalls. Ranitidine is available over the counter (OTC) and as a prescription to decrease the production of stomach acid.&ldquo;The FDA is not calling for individuals to stop taking ranitidine at this time; however, patients taking prescription ranitidine who wish to discontinue use should talk to their healthcare professional about other treatment options,&rdquo; the FDA said in a press release. &ldquo;People taking OTC ranitidine could consider using other OTC medicines approved for their condition.&rdquo;The European Medicines Agency is also reviewing ranitidine medicines.&nbsp;The FDA said it is working with international regulators and industry partners to determine the source of this impurity in ranitidine.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

FDA Says Some Heartburn Drugs May be Linked to Cancer

Oncology

The U.S. Food and Drug Administration (FDA) warned that some heartburn drugs, including Zantac® (ranitidine), contain low levels of N-nitrosodimethylamine (NDMA), a ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe